FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular, to an antibody for antigen-antibody interaction with claudin 6 (CLDN6) located on the surface of cells expressing CLDN6, substantially incapable of antigen-antibody interaction with other highly homologous claudins, as well as to an immunoconjugate, a pharmaceutical composition containing said antibody. Hybridomas are also disclosed for producing said antibody. Invention also relates to a method of inhibiting the growth of a cell expressing CLDN6, to a method of destroying a cell expressing CLDN6, to a method of treating or preventing cancer involving a cell expressing CLDN6, as well as a method for inhibiting metastatic spread of a cell expressing CLDN6, using said antibody and / or immunoconjugate.
EFFECT: invention makes it possible to efficiently destroy cells expressing CLDN6.
32 cl, 26 dwg, 1 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
| ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6 | 2012 |
|
RU2676731C2 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| AGENTS FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | 2013 |
|
RU2678127C2 |
| ANTIBODIES USEFUL IN DIAGNOSING CANCER | 2018 |
|
RU2815883C1 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| DIAGNOSTICS AND TREATMENT OF CANCER ASSOCIATED WITH CANCER STEM CELLS | 2014 |
|
RU2749867C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
